Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Int Arch Allergy Immunol. 2005 Sep;138(1):29-39. Epub 2005 Aug 8.

    Antigen-induced reduction in mast cell and basophil functional responses due to reduced Syk protein levels.

    Source

    Division of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Virginia Commonwealth University Health Systems, Richmond, VA 23298, USA. clkepley@vcu.edu

    Abstract

    BACKGROUND:

    The high-affinity IgE receptor, FcepsilonRI, is unresponsive on mast cells and basophils from people in several populations through an unknown mechanism. Similarly, FcepsilonRI-positive basophils from 'nonreleasers' are IgE-unresponsive and are deficient in the tyrosine kinase Syk.

    OBJECTIVE:

    To test the hypothesis that cross-linking FcepsilonRI on mast cells and basophils leads to FcepsilonRI nonresponsiveness through reduction in Syk protein levels.

    METHODS:

    Human mast cells and basophils were used to determine if FcepsilonRI hyporesponsiveness correlated with reduced Syk levels.

    RESULTS:

    It is shown that suboptimal antigen challenge, that did not lead to significant mediator release, induced nonresponsiveness and correlated with reduced Syk. Other IgE-associated signaling molecules were unaffected by the same treatment. The ability of IgE-unresponsive mast cells to regain FcepsilonRI responsiveness is paralleled by increased cellular Syk levels in vitro. The reduction of Syk levels with suboptimal antigen concentrations was calcium independent and mediated through a proteasome-dependent mechanism.

    CONCLUSION:

    These findings confirm and extend our knowledge about a novel regulatory mechanism for maintaining FcepsilonRI in a quiescent state. This mechanism may also explain why low concentrations of allergen given to patients during allergen immunotherapy induce FcepsilonRI nonresponsiveness and therapeutic benefit without inducing systemic anaphylaxis.

    Copyright (c) 2005 S. Karger AG, Basel.

    PMID:
    16088210
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for S. Karger AG, Basel, Switzerland

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk